文献速递前列腺增生与排尿功能障碍

米拉贝隆与维贝格隆治疗初治女性膀胱过度活动症的随机对照研究比较

Comparison of Mirabegron and Vibegron in Women With Treatment-Naive Overactive Bladder: A Randomized Controlled Study.
PubMed 文献 · Urology · 2023-02-22

该前瞻性随机对照研究纳入199例初治膀胱过度活动症绝经后女性,分别接受米拉贝隆50 mg/日或维贝格隆50 mg/日治疗12周。两组OABSS、QOL指数及排尿日记参数较基线均显著改善,组间变化率无显著差异,因不良反应停药率分别为6.2%和6.8%,无显著差异。

要点

  • 米拉贝隆50 mg与维贝格隆50 mg均改善初治OAB绝经后女性症状及排尿日记参数。
  • 治疗12周时两组OABSS、QOL指数及排尿日记参数变化率无显著差异。
  • 因不良反应停药率米拉贝隆组6.2% vs 维贝格隆组6.8%,无显著差异。

核心结论

  • 米拉贝隆50 mg与维贝格隆50 mg对初治OAB绝经后女性症状及排尿日记参数的改善程度相当。

研究设计与样本

  • 前瞻性随机对照研究,213例初治OAB女性入组,199例随机分为米拉贝隆组(n=97)或维贝格隆组(n=102),分层随机法给药50 mg/日,疗程12周。

主要发现

  • 治疗12周后,两组OABSS、QOL指数、每24小时排尿次数、尿急发作次数、尿失禁发作次数及每次排尿量均较基线显著改善,组间变化率无显著差异。
  • 治疗12周时两组残余尿量无显著差异。
  • 因不良反应停药率米拉贝隆组6.2% vs 维贝格隆组6.8%,两组间无显著差异。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare the efficacy and safety of mirabegron versus vibegron in postmenopausal women with treatment-naïve overactive bladder (OAB). METHODS: We conducted a prospective randomized controlled study of women with treatment-naïve OAB. The patients received mirabegron or vibegron at 50 mg daily for 12 weeks by a stratified randomized method. The OAB symptom score (OABSS) and quality of life (QOL) index were evaluated before and 4 and 12 weeks after the treatment. The patients' 3-day voiding diary and postvoided residual urine volumes were evaluated before and 12 weeks after the treatment. RESULTS: Of 213 patients initially enrolled in this study, 199 patients were randomized to the mirabegron group (n = 97) or vibegron group (n = 102). Twelve weeks after the treatment, OABSS, QOL index, the numbers of micturition, urgency episodes, incontinence episodes, and voided volume per 24 hours were significantly improved compared with the baseline in both groups, and there was no significant difference in the rate of change in both groups. The postvoid residual urine volume was not significantly different in the 2 groups at 12 weeks. Discontinuation because of adverse effects was observed in 6.2% of patients in the mirabegron group and 6.8% in the vibegron group, with no significant difference between 2 groups. CONCLUSION: Both mirabegron at 50 mg and vibegron at 50 mg improved OAB symptoms and the parameters of voiding diary equally in postmenopausal women with treatment naïve OAB.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Kinjo M, Masuda K, Nakamura Y, et al. Comparison of Mirabegron and Vibegron in Women With Treatment-Naive Overactive Bladder: A Randomized Controlled Study. Urology. 2023. PMID: 36822245. doi:10.1016/j.urology.2023.02.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。